Copyright © 2003 by the European Society of Cardiology.
Regular Articles
Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement
Deutsches Herzzentrum München and 1. Medizinische Klinik rechts der Isar, Technische Universität München, Lazarettstrasse 36, 80636 München, Germany
* Corresponding author. Tel.: +49-89-12182601; fax: +49-89-12183053
E-mail address: wkoch{at}dhm.mhn.de
Received 8 November 2002; accepted 20 November 2002
Aims Endothelial nitric oxide synthase (eNOS) catalyzes the formation of nitric oxide which has vasodilatory, antithrombotic, antiinflammatory and antiproliferative properties. The TT genotype of the single nucleotide polymorphism 894 G/T, located in exon 7 of the eNOS gene, was found to be associated with coronary spasm, coronary artery disease (CAD) and myocardial infarction (MI). We investigated the possibility that the 894 TT genotype has an unfavorable impact on the angiographic and clinical outcome after the placement of stents in coronary arteries.
Methods and results Our study included 1850 patients with CAD who were treated with stent implantation. Major adverse clinical events, including death, MI, and target vessel revascularization, were recorded for 1 year after the intervention. Patients with genotype 894 TT had an increase in the risk of death or MI (hazard ratio 2.14, 95% confidence interval (CI) 1.23–3.72; 
), if compared with G allele carriers. TT patients showed no significant increase in the risk for angiographic restenosis (odds ratio (OR) 1.11, 95% CI 0.78–1.56; 
) and target vessel revascularization (OR 1.21, 95% CI 0.82–1.78; 
).
Conclusions In comparison with eNOS 894 G allele carriers, patients of the TT genotype were at an increased risk of death or MI within 1 year after coronary artery stenting.
Key Words: Endothelial nitric oxide synthase • Stents • Adverse outcome • Myocardial infarction • Restenosis • Genetics
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Galluccio, P. Piatti, L. Citterio, P. C. G. Lucotti, E. Setola, L. Cassina, M. Oldani, I. Zavaroni, E. Bosi, A. Colombo, et al. Hyperinsulinemia and impaired leptin-adiponectin ratio associate with endothelial nitric oxide synthase polymorphisms in subjects with in-stent restenosis Am J Physiol Endocrinol Metab, May 1, 2008; 294(5): E978 - E986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Casas, G. L. Cavalleri, L. E. Bautista, L. Smeeth, S. E. Humphries, and A. D. Hingorani Endothelial Nitric Oxide Synthase Gene Polymorphisms and Cardiovascular Disease: A HuGE Review Am. J. Epidemiol., November 15, 2006; 164(10): 921 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Antoniades, D. Tousoulis, C. Vasiliadou, C. Pitsavos, C. Chrysochoou, D. Panagiotakos, C. Tentolouris, K. Marinou, N. Koumallos, and C. Stefanadis Genetic Polymorphism on Endothelial Nitric Oxide Synthase Affects Endothelial Activation and Inflammatory Response During the Acute Phase of Myocardial Infarction J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1101 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Nagassaki Functional implications of polymorphisms of endothelial nitric oxide synthase gene Eur. Heart J., February 1, 2004; 25(3): 277 - 278. [Full Text] [PDF]
|
|
|
|
|
|
W. Koch, O. Gorchakova, N. von Beckerath, A. Kastrati, and A. Pfeufer Functional implications of polymorphisms of endothelial nitric oxide synthase gene: Reply Eur. Heart J., February 1, 2004; 25(3): 278 - 278. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Erbs, A. Linke, G. Schuler, and R. Hambrecht Promoter and Exon 7 Polymorphism of Endothelial Nitric Oxide Synthase: Impact on Endothelial Function and Its Correction by Exercise Training in Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): e12 - 12. [Full Text]
|
|